Email: jwangliu@163.com

Introduction: 
I was born in Anhui, China and I received BS degree from Anhui University of Chinese Medicine in 2017. I'm currently a fourth-year graduate student in the research group of Professor Li at East China University of Science and Technology and major in computer aided drug design

Education Background:
2017-present, Pharmacy, East China University Of Science And Technology.
2013-2017, B.E., Pharmaceutical Preparations, Anhui University of traditional Chinese Medicine.

Publication:
1. Tong Zhao, Jie Wang, Yidi Chen, Shan Wang, Jian Lu, Jianlu Lv, Shiliang Li, Jiaying Wang, Minyi Qian*, Honglin Li*, Xu Shen*. Antiallergic drug Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist. Metabolism, 2021. 119 : 154771.

2. Disha Wang, Wenjun Liu, Zihao Shen, Lei Jiang, Jie Wang, Shiliang Li*, Honglin Li*. Deep Learning Based Drug Metabolites Prediction. Front. Pharmacol., 2020. 10 : 1586.

3. Zhicheng Su, Tingyuan Yang, Jie Wang, Mengzhen Lai, Linjiang Tong, Gulinuer Wumaier, Zhuo Chen*, Shengqing Li, Honglin Li, Hua Xie*, Zhenjiang Zhao*. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. Bioorg. Med. Chem. Lett., 2020. 30(16) : 127327.

4. Jie Wang, Shiliang Li, Honglin Li*. Drug design of "undruggable" targets. Chin. J. Chem., 2019. 37 : 501-512.